When are medical apps medical? Off-label use and the Food and Drug Administration

被引:3
|
作者
Krieger, William H. [1 ]
机构
[1] Univ Rhode Isl, Kingston, RI 02881 USA
来源
DIGITAL HEALTH | 2016年 / 2卷
关键词
Medical apps; Food and Drug Administration; mobile healthcare; off-label; conflict of interest;
D O I
10.1177/2055207616662782
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or 'apps' on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing mobile healthcare sector, the Food and Drug Administration has put forth guidelines to regulate 'mobile medical apps' (MMAs), those health-related apps that are (self) designated as medical devices. In this article, I argue that this decision, to only regulate apps that bill themselves as medical devices, will create a market for 'off-label' app use. Further, I will talk about the oft used analogy between off-label apps and off-label pharmaceuticals, showing that off-labeling apps will provide patients none of the benefits that come with a physician prescribing a drug off-label, while exposing the mobile healthcare consumer to significant risks that go significantly beyond those that we know of (and must accept) from prescription drugs. Recognizing that the Food and Drug Administration is not going to be able to significantly change its policies on oversight, I will suggest specific actions to at least mitigate some of the risks associated with off-label app use.
引用
收藏
页数:12
相关论文
共 50 条
  • [22] Off-Label Use of Drugs and Medical Devices: A Review of Policy Implications
    Stafford, R. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (05) : 920 - 925
  • [23] A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs
    Smithburger, Pamela L.
    Buckley, Mitchell S.
    Culver, Mark A.
    Sokol, Sarah
    Lat, Ishaq
    Handler, Steven M.
    Kirisci, Levent
    Kane-Gill, Sandra L.
    CRITICAL CARE MEDICINE, 2015, 43 (08) : 1612 - 1621
  • [24] Off-label Drug Use and Adverse Drug Events Turning up the Heat on Off-label Prescribing
    Good, Chester B.
    Gellad, Walid F.
    JAMA INTERNAL MEDICINE, 2016, 176 (01) : 63 - 64
  • [25] US food and drug administration and off-label use of expandable metal biliary Stents within the peripheral vasculature
    Yustein, Aron S.
    Schultz, Daniel
    Neuland, Carolyn
    Buckles, David S.
    Nipper, Joshua C.
    Stephenson, Rebecca A.
    Gonzalez, Gema
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2008, 19 (07) : 965 - 969
  • [26] THE USE OF FOOD AND DRUG ADMINISTRATION-APPROVED MEDICATIONS FOR UNLABELED (OFF-LABEL) USES - THE LEGAL AND ETHICAL IMPLICATIONS
    TORRES, A
    ARCHIVES OF DERMATOLOGY, 1994, 130 (01) : 32 - 36
  • [27] Off-Label Use of Drugs and Devices: Role of Medical Professionals in the Establishment of Parameters for Their Use
    Long, Donlin
    Watts, Clark
    NEUROSURGERY, 2013, 72 (06) : 1014 - 1020
  • [28] Off-Label Drug Use: The Bevacizumab Story
    Stewart, Michael W.
    MAYO CLINIC PROCEEDINGS, 2013, 88 (03) : 305 - 305
  • [29] OFF-LABEL DRUG USE IN CHILDHOOD ASTHMA
    Kling, Sharon
    CURRENT ALLERGY & CLINICAL IMMUNOLOGY, 2011, 24 (01) : 38 - 41
  • [30] Off-label prescription drug use in children
    McPhillips, HA
    Davis, RL
    Hecht, JA
    Stille, CJ
    PEDIATRIC RESEARCH, 2003, 53 (04) : 205A - 205A